FDA clears Aprea Therapeutic’s Investigational New Drug (IND) application (IND 169359) for oral WEE1 Inhibitor, APR-1051
Aprea to initiate the Phase 1 ACESOT-1051 trial. Learn more

We’re Forging New Pathways in the Fight Against Cancer.


Our diversified portfolio of clinical and pre-clinical assets presents a pioneering new approach that doesn’t sacrifice tolerability for efficacy.

Aprea’s precision oncology pioneers develop highly selective, potentially less toxic DDR-targeted therapeutics that are designed to address a significant unmet medical need for cancer patients with mutations in DNA damage response (DDR) genes.

Our diversified portfolio of clinical and pre-clinical assets presents a pioneering new approach that maximizes efficacy by improving tolerability.

DDR-Targeted Solutions


Aprea’s unique approach to synthetic lethality is revolutionizing the future of cancer treatment.

Pipeline


Aprea’s robust pipeline explores multiple targets to improve our chances of success.

Clinical Trials

Clinical trials put Aprea closer to bringing breakthrough DDR-targeted therapies to market.

Team


Our experienced management and board of directors values the role of investors in our mission to save lives.

A Groundbreaking Approach to DDR-Targeted Therapeutics